FDA/CDC

FDA grants priority review of acalabrutinib for second-line treatment of MCL

Publish date: August 2, 2017
By
Laura Nikolaides

 

The Food and Drug Administration has granted a priority review for acalabrutinib, a Bruton tyrosine kinase inhibitor, for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

The new drug application is based on results from the phase 2 ACE-LY-004 trial, which evaluated the safety and efficacy of acalabrutinib in patients with relapsed/refractory MCL who had received at least one prior therapy.

Results from the trial will be submitted for presentation at a forthcoming medical meeting, makers of the drug AstraZeneca said in a press release announcing the priority review. The company also has a phase 3 trial underway evaluating acalabrutinib as a first-line treatment for patients with MCL.

On Twitter @NikolaidesLaura

Recommended Reading

Four drugs better than three for myeloma induction
MDedge Hematology and Oncology
FLT3-L level may point to relapsed/refractory multiple myeloma
MDedge Hematology and Oncology
Less lenalidomide may be more in frail elderly multiple myeloma patients
MDedge Hematology and Oncology
Delirium linked to early death in advanced cancer patients
MDedge Hematology and Oncology
FDA grants acalabrutinib breakthrough designation
MDedge Hematology and Oncology
Understanding childhood cancer in sub-Saharan Africa
MDedge Hematology and Oncology
ASCO updates guidelines on antiemetic use in cancer patients
MDedge Hematology and Oncology
Developing better mouse models
MDedge Hematology and Oncology
Health Canada approves new use for brentuximab vedotin
MDedge Hematology and Oncology
Clinical Endpoints in PTCL: The Road Less Traveled
MDedge Hematology and Oncology